ClinicalTrials.gg
RecruitingNCT05497609CPBiopsyBTXUpdated Aug 11, 2022

The Muscle in Children With Cerebral Palsy - Longitudinal Exploration of Microscopic Muscle Structure.

An observational study in Cerebral Palsy, Muscle Contraction and Muscle Spasticity, sponsored by Eva Ponten. Recruiting at 1 site in Sweden. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-08-11.

Sponsored by Eva Ponten · Observational

How we know

From the registry’s dates

  • Started Jan 2006; still recruiting 20 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Cerebral Palsy with a site in Sweden — 9 open to participants now, 10 under way, none of them phase 3. Cerebral Palsy · Sweden.

Started
2006
the only one that year
Observational
9 of 19
6 open now
Registered
11th of 19
by date
Lead sponsor
3 of 19
Eva Ponten

Among the 19 studies in Cerebral Palsy with a site in Sweden, this one is the only one that started in 2006, is one of 9 observational ones, and was the 11th registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

9 of the 19 studies in Cerebral Palsy with a site in Sweden are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Cerebral Palsy with a site in Sweden, or all of them as a file.
02

Study summary

Cerebral palsy (CP) is a motor impairment due to a brain malformation or a brain lesion before the age of two. Spasticity, hypertonus in flexor muscles, dyscoordination and an impaired sensorimotor control are cardinal symptoms. The brain lesion is non-progressive, but the flexor muscles of the limbs will during adolescence become relatively shorter and shorter (contracted), forcing the joints into a progressively flexed position. This will worsen the positions of already paretic and malfunctioning arms and legs. Due to bending forces across the joints, bony malformations will occur, worsening the function even further. Since about 25 years a combination treatment with intramuscular botulinum toxin injections, braces and training has had a tremendous and increasing popularity, although lasting long-term clinical advantage is not yet proven.

Muscle morphology of the biceps brachii and the gastrocnemius muscles:

  • The hypothesis is that care as usual, i.e. training and splinting sessions with botulinum toxin as adjuvant treatment, will reduce (normalize) the expression of the fast fatigable myosin heavy chain MyHC IIx and increase the expression of developmental myosin, as a possible sign of growth. As the biceps in the arm is used irregularly and voluntarily, and the gastrocnemius is activated during automated gait, the adaptations of those muscles will be different. Methods: Baseline muscle biopsies: Percutaneous biopsies are taken just before the first intramuscular botulinum toxin injection is given. The doses and the intervals for the botulinum toxin treatment will follow clinical routines. Biopsies 4-6 months, 12 months and 24 months after the first botulinum toxin injection: The exact same procedure as above will be performed, but the biopsies will be taken 2 cm distant, medial or lateral, from previous biopsy sites
  • Significance:. More knowledge is warranted regarding the actual molecular process in the muscle leading to a contracture, and its relation to the constant communication with the injured central nervous system. This study will give answers that could result in new, early prophylactic treatment of joint movement restrictions and motor impairment in children with CP.
Read the detailed description

Cerebral palsy (CP) is a motor impairment due to a brain malformation or a brain lesion before the age of two. Spasticity, hypertonus in flexor muscles, dyscoordination and an impaired sensorimotor control are cardinal symptoms. The brain lesion is non-progressive, but the flexor muscles of the limbs will during adolescence become relatively shorter and shorter (contracted), forcing the joints into a progressively flexed position. This will worsen the positions of already paretic and malfunctioning arms and legs. Due to bending forces across the joints, bony malformations will occur, worsening the function even further. Currently, the initial treatment of choice is the use of braces, which diminishes the shortening somewhat. Since about 25 years a combination treatment with intramuscular botulinum toxin injections, braces and training has had a tremendous and increasing popularity, although lasting long-term clinical advantage is not yet proven.

Muscle morphology of the biceps brachii and the gastrocnemius muscles:

  • The hypothesis is that care as usual, i.e. training and splinting sessions with botulinum toxin as adjuvant treatment, will reduce (normalize) the expression of the fast fatigable myosin heavy chain MyHC IIx and increase the expression of developmental myosin, as a possible sign of growth. As the biceps in the arm is used irregularly and voluntarily, and the gastrocnemius is activated during automated gait, the adaptations of those muscles will be different. Methods: Baseline muscle biopsies: Percutaneous biopsies from the biceps brachii and the gastrocnemius muscles are taken just before the first intramuscular botulinum toxin injection is given. The doses and the intervals for the botulinum toxin treatment will follow clinical routines. Training of the leg and arm will after the injections be performed with the help of physiotherapists and occupational therapists. Biopsies 4-6 months, 12 months and 24 months after the first botulinum toxin injection: The exact same procedure as above will be performed, but the biopsies will be taken 2 cm distant, medial or lateral, from previous biopsy sites. The muscle specimens are snap frozen and stored at -80°C until analyzed. The expression of different myosin heavy chain (MyHC) isoforms is assessed by using the monoclonal antibodies (mAb) N2.261, mAb A4.840 against slow MyHC I, mAb F1.652 against embryonic MyHC, and mAb NCL-MHCn against fetal (=neonatal) MyHC)(Tiger, Champliaud et al. 1997; Wewer, Thornell et al. 1997). Satellite cells will be identified with mAb against N-CAM (neural cell adhesion molecule). The fibers are typed according to the content of MyHCs.

Significance: Children with cerebral palsy have a motor impairment and progressive contractures that we often treat late; when tendon and bony surgery are the only options to realign the joints. Our aim is to treat the muscles early, so that the contractures and the bony malformations won't occur in the first place. Training and splints, with botulinum toxin as adjuvant treatment, is a very popular regime with this aim, but the long-term effect on muscle tissue and function is not yet known. This study will elucidate the effect during a 2-year period, and no such studies have yet been published. More knowledge is warranted regarding the actual molecular process in the muscle leading to a contracture, and its relation to the constant communication with the injured central nervous system. This study will give answers that could result in new, early prophylactic treatment of joint movement restrictions and motor impairment in children with CP.

03

Conditions studied

  • Cerebral Palsy
  • Muscle Contraction
  • Muscle Spasticity

Keywords

  • Cerebral Palsy
  • Upper Limb
  • Lower Limb
  • Muscle Biopsy
  • Botulinum Toxin Type A
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children with cerebral palsy and aquired brain injury who, as a part of care as usual, gets botulinum toxin injections in muscles. Children are recruited consecutively.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cerebral Palsy, Aquired Brain Injury

Exclusion criteria

Exclusion Criteria:

  • Progressive neural disease
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Otherno intervention. Care as ususal

    No intervention

06

What researchers measure

Primary outcomes

  1. Muscle fiber area

    um2, square micrometers, measured on specimens

    Time frame: Biopsies are collected and stored in -80° freezer and then analyzed. Analyses will take place up to 20271215

  2. Muscle fiber types based on myosin heavy chain isoforms

    Percentage of all fibers

    Time frame: Biopsies are collected and stored in -80° freezer and then analyzed. Analyses will take place up to 20271215

  3. Extracellular matrix, area

    um2, square micrometers, measured on specimens

    Time frame: Biopsies are collected and stored in -80° freezer and then analyzed. Analyses will take place up to 20271215

  4. Capillaries per fiber area

    number of capillaries/um2

    Time frame: Biopsies are collected and stored in -80° freezer and then analyzed. Analyses will take place up to 20271215

  5. Mitochondria: NADH staining, morphology

    Scoring 1, 2, 3

    Time frame: Biopsies are collected and stored in -80° freezer and then analyzed. Analyses will take place up to 20271215

Secondary outcomes

  1. Clinical assessment, contracture

    °, degrees

    Time frame: At 0 months, 6 months, 12 months and 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2006 (actual). Primary completion is estimated for Dec 2026, 251 months after the start.

Of 217 non-industry observational studies under Cerebral Palsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 60. This study's planned 251 months is above that.

Counting every sponsor, half of 221 studies reached it within 21 months; a quarter within 8 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2022
First posted
Aug 11, 2022
StartActual
Jan 15, 2006
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 15, 2027
Last update
Aug 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05497609
Lead sponsor
Eva Ponten
Responsible party
Eva Ponten (MD PhD Ass Prof, Region Stockholm) — Sponsor-investigator
First posted
Aug 11, 2022
Start date
Jan 15, 2006
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Aug 11, 2022

Study contacts

Eva M Pontén, MD PhD
Contact
eva.ponten@ki.se
+46706303052
Alexandra Palmcrantz
Contact
alexandra.palmcrantz@ki.se
Eva M Pontén, MD PhD
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion